# OnCo record ann-lii-cheng (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/ann-lii-cheng/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "ann-lii-cheng" ;
  schema:name "Ann-Lii Cheng"@en ;
  schema:description "Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer."@en ;
  schema:url <https://onco.cc/people/ann-lii-cheng/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20AL%5BAuthor%5D%20hepatocellular> ;
  onco:tag "hcc", "immunotherapy", "asia" ;
  schema:jobTitle "Distinguished Professor and Director, National Taiwan University Cancer Center" ;
  schema:sameAs <https://orcid.org/0000-0002-9152-6512> ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/> ;
  onco:institutions <https://onco.cc/institutions/ntuh/> ;
  onco:trials <https://onco.cc/trials/imbrave150/>, <https://onco.cc/trials/reflect/>, <https://onco.cc/trials/imbrave050/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-imbrave150-nejm-2020/> ;
  schema:affiliation <https://onco.cc/institutions/ntuh/> .